Factors known to have an impact on bedaquiline exposure are present in patients with M/XDR-TB. As we have seen with fluoroquinolones the impact of variable drug exposure needs to be studied to understand the impact on treatment outcome.http://bit.ly/2JMlJJF
No takes yet. Share an insight, caveat, or question.
Alffenaar et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: